# CervoMed Inc. Common Stock (CRVO)

> CervoMed Inc. Common Stock (CRVO) trades at $1.46 (+9.77%) as of 7:59:43 PM EST on Nov 20, 2026, -34.82% over the past month. Market cap is $22.09M, with 4.7 days to cover in short interest.

Canonical: https://massive.com/quote/crvo
Data as of: 2026-11-21T00:59:43.220Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$1.46** +0.13 (+9.77%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$1.44** -0.02 (-1.37%)
As of 7:59:43 PM EST on Nov 20, 2026 · After hours

## Stock performance

How CervoMed Inc. Common Stock (CRVO) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +9.77% |
| 1W | -13.61% |
| 1M | -34.82% |
| YTD | -81.52% |
| 1Y | -84.25% |
| 52-wk range | $1.27 – $10.00 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for CRVO: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $1.40 – $1.65 |
| Open | $1.53 |
| Prev close | $1.33 |
| Volume | 1.2M |
| Market cap | $22.09M |
| Shares out | 15.13M |

## Valuation and profitability ratios

Valuation and profitability ratios for CervoMed Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 2531.25 |
| P/B | 1.27 |
| P/FCF | — |
| ROE | -164.3% |
| ROA | -133.7% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 20, 2026

## Insider trading

[CervoMed Inc. Common Stock (CRVO) insider trading](https://massive.com/quote/crvo/insider-trading.md): open-market Form 4 buys and sells by CervoMed Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events CervoMed Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 16, 2026 · Investor presentation
  “On November 16, 2026, CervoMed Inc. issued a press release announcing the presentation of 24-week interim biomarker data from its ongoing Phase 2a clinical trial of neflamapimod in patients with nonfluent variant primary progressive aphasia at the 19th Clinical Trials on Alzheimer's Disease Conference.”
- Nov 9, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 9, 2026, CervoMed Inc. issued a press release announcing financial results as of and for the quarter ended September 30, 2026.”
- Oct 14, 2026 · Investor presentation
  “Certain information concerning the business, clinical studies, development plans, financial position, and related matters of CervoMed Inc. is being made available on our website, www.cervomed.com, under the heading, “Investors – Events and Presentations.” Representatives of the Company may use this presentation ... in connection with conferences, meetings, and presentations to investors, analysts and others.”
- Oct 13, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “On October 12, 2026, CervoMed Inc. issued a press release announcing initial data from the first 12 weeks of the Company's Phase 2a clinical trial in nonfluent variant primary progressive aphasia ("nfvPPA"), which were presented in a late-breaking oral presentation at the 15th International Society of Frontotemporal Dementias Annual Meeting.”
- Oct 9, 2026 · Investor presentation
  “Certain information concerning the business, clinical studies, development plans, financial position, and related matters of CervoMed Inc. is being made available on our website, www.cervomed.com, under the heading, “Investors – Events and Presentations.” Representatives of the Company may use this presentation ... in connection with conferences, meetings, and presentations to investors, analysts and others.”

## Dividend history and stock splits

CervoMed Inc. Common Stock's recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-50 · Apr 19, 2022
- 1-for-15 · Dec 14, 2018

## CRVO short interest

How heavily CRVO is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 4.7 |
| Short interest | 1.21M |
| Avg volume | 260.59K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## CRVO news

The latest news and headlines about CervoMed Inc. Common Stock (CRVO).

- [Agenus (AGEN) Q3 Earnings Meet Estimates](https://www.zacks.com/stock/news/3025037/agenus-agen-q3-earnings-meet-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3025037) · Zacks Investment Research · Nov 5, 2026 · negative sentiment
- [CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis](https://www.globenewswire.com/news-release/2026/02/18/3240007/0/en/CervoMed-s-neflamapimod-elected-for-inclusion-in-UK-EXPERTS-ALS-platform-designed-to-prioritize-promising-treatments-for-Amyotrophic-Lateral-Sclerosis.html) · GlobeNewswire Inc. · Feb 18, 2026 · positive sentiment
- [CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies](https://www.globenewswire.com/news-release/2025/12/04/3200383/0/en/CervoMed-Announces-Late-Breaking-Data-at-the-18th-CTAD-Conference-Demonstrating-Neflamapimod-Significantly-Slows-Clinical-Progression-in-Dementia-with-Lewy-Bodies.html) · GlobeNewswire Inc. · Dec 4, 2025 · positive sentiment
- [CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)](https://www.globenewswire.com/news-release/2025/12/02/3197738/0/en/CervoMed-Presents-New-Plasma-Biomarker-Data-That-Indicates-Neflamapimod-Broadly-Improves-Neuroinflammation-and-Neurodegeneration-in-Dementia-with-Lewy-Bodies-DLB.html) · GlobeNewswire Inc. · Dec 2, 2025 · positive sentiment
- [CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference](https://www.globenewswire.com/news-release/2025/11/24/3193345/0/en/CervoMed-to-Share-New-Data-on-Neflamapimod-as-a-Treatment-for-Dementia-with-Lewy-Bodies-at-the-18th-Clinical-Trials-on-Alzheimer-s-Disease-CTAD-Conference.html) · GlobeNewswire Inc. · Nov 24, 2025 · positive sentiment

## About CervoMed Inc. Common Stock

CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 15 |
| Listed | Jun 18, 1996 |

[Company website](https://www.cervomed.com)

## FAQ

### What is the CervoMed Inc. Common Stock (CRVO) stock price today?

CervoMed Inc. Common Stock (CRVO) is trading at $1.46 (+9.77% on the day) as of 7:59:43 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is CervoMed Inc. Common Stock?

CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the…

### What is the short interest in CRVO?

As of Oct 30, 2026, CRVO has 1.21M shares short and 4.7 days to cover.

### What exchange is CRVO listed on?

CervoMed Inc. Common Stock (CRVO) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time CRVO quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=CRVO`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [CervoMed Inc. Common Stock (CRVO) insider trading](https://massive.com/quote/crvo/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
